of therapeutic nucleic acids
Altamira Therapeutics is developing OligoPhore™ / SemaPhore™ as a versatile platform for safe and effective delivery of nucleic acid payloads such as siRNA (small interfering ribonucleic acid), mRNA (messenger ribonucleic acid) into target cells, using systemic or local administration.
siRNA is one type of oligonucleotide which can be used therapeutically to silence disease-related genes in a specific manner.
mRNA can be used therapeutically to translate genetic code from DNA into proteins, which then can be used to replace abnormal or deficient proteins or make proteins to fight or prevent disease.
The Greek word “phore” means an agent or bearer or producer of a specified thing. OligoPhore™ allows for carrying oligonucleotides such as siRNA into cells. The Greek word “sema” means a signal or message. SemaPhore™ allows for carrying messenger RNA into cells.
Our OligoPhore™ / SemaPhore™ technology has been tested in numerous standard murine models, both with siRNA and mRNA payloads. Several key features of the nanoparticles have emerged from these studies:
RNA complexed in nanoparticle format remains stable in the blood circulation and is only released inside of cells after uptake
The nanoparticles are not sequestered in the liver, but reach other tissues
Efficient endosomal escape
pH-dependent nanoparticle disassembly, followed by full release of RNA into the cytoplasm
The nanoparticles can be administered systemically, but target only diseased tissues
No cellular or adaptive immune responsivity to nanoparticle components or RNA after multiple serial doses and no organ toxicities have been observed